Pharmacy Technician Pulse

Why is the healthcare industry hesitant to join the metaverse?

Pharmaceutical Technology

APRIL 24, 2023

The Covid-19 pandemic pushed the healthcare industry toward rapid digitalisation, with the rise of telehealth, telepresence systems, remote diagnostics, predictive AI, and wearable technology now changing the way healthcare is delivered and improving patient outcomes.

Hospitals

Stanford Health CEO David Entwistle joins Redesign Health's board. Here's why he's bullish on digital health

Fierce Healthcare

AUGUST 17, 2023

Stanford Health Care CEO David Entwistle joined the board of directors at New York City-based Redesign Health. David Entwistle has a storied career as a healthcare executive leading new innovations and steering strategic growth at academic medical centers. Here are the areas of healthcare he thinks are ripe for innovation.

Best of the Best: Delaney Santon, CPHT, on How Pharmacy Techs Help Patients

Drug Topics

DECEMBER 9, 2022

Winner of SingleCare's Best of the Best: Best Pharmacy Technician, Santon joined Drug Topics® to discuss what pharmacy technicians can do for patients and why it's so important to her for every patient to afford their medication.

CPhT

Opinion: Independent doctors like me are becoming an endangered species

STAT

FEBRUARY 15, 2024

As an independent physician, I know exactly why so many are making that choice. Luckily, I was able to join forces with other local independent docs to form a bigger group practice. Today, nearly three in four physicians are employees of larger health care entities or other corporations — a record high.

Hospitals

Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard

STAT

MARCH 14, 2024

Why don’t patients want gene therapy? Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development. What happens when an approved drug doesn’t work? And is MASH still a big deal?

Listen: VC turmoil, GLP-1 competition, & the war on recovery

STAT

MARCH 7, 2024

Why are addiction treatments so hard to get? STAT’s Lev Facher joins us to explain his reporting on why virtually every sector of American society is standing in the way of their use. Can small companies compete in obesity? And since when is “Series E” a thing in biotech? Read the rest…

Evotec to advance drug discovery in collaboration with the Crohn’s & Colitis Foundation

Outsourcing Pharma

JANUARY 10, 2024

Evotecâs end-to-end integrated research and development platform will be able to advance drug discovery for two drug targets which is why it has joined forces with the Crohnâs & Colitis Foundation.

Why a Microbiology Forum is Worth your Time

Pharmig

FEBRUARY 9, 2024

Learn how joining a scientific forum could benefit you and your career online today. The post Why a Microbiology Forum is Worth your Time appeared first on Pharmig. Pharmaceutical microbiology forums are here to keep you on your toes.

Biotech layoffs, slumping stocks, and a 2024 preview

STAT

JANUARY 18, 2024

Why are rich biotechs cutting costs? Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. Has JPM Week already worn off? And what’s going to move markets in 2024?

FDA

Listen: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise

STAT

APRIL 4, 2024

Why is it surprising when drug executives stay true to their word? Oruka Therapeutics CEO Lawrence Klein joins us to discuss how his company raised its first round of financing before competing with major players in the inflammation space. And can neoantigen cancer vaccines work?

Vaccines

Watch DSN: Walmart Marketplace helps expand product reach to consumers

Drug Store News

MAY 2, 2023

Marketplace and Walmart Fulfillment Services, about why now is the ideal time for new sellers to join the marketplace. DSN spoke to Manish Joneja, senior vice president of Walmart U.S.

Prepare for Winter Respiratory Season Testing Needs

Drug Topics

NOVEMBER 7, 2022

Drug Topics® is joined by Joseph Mann, MSN, FNP-C, to discuss the impact of the CDC's streamlined COVID-19 guidance on pharmacy, how pharmacists can prepare for testing demand during the winter respiratory season, and why taking a proactive approach is so important.

Listen: ESMO highlights, Roivant’s big deal, & biotech VC on the rise

STAT

OCTOBER 26, 2023

And why are venture capitalists so optimistic? Our colleague Andrew Joseph joins us to explain the decades-old cancer-treating technology that had its star turn at this week’s big oncology conference in Europe. How do cancer drugs work? What makes biotech stocks go up?

Listen: Racing for gene therapy, a pioneering approval, & startups in the lurch

STAT

AUGUST 17, 2023

Our colleague Jason Mast joins us to explain how the approval of a landmark gene therapy for Duchenne muscular dystrophy set in motion a frantic race to get children treated before their 6th birthdays. Then, HSBC Managing Director Jonathan Norris calls in to discuss why so many biotech startups are facing financial bridges to nowhere.

Listen: Wegovy in the brain, pivotal Alzheimer’s data, & pulling Threads

STAT

JULY 13, 2023

Our colleague Megan Molteni joins us to explain the evolving science suggesting products like Wegovy are less weight loss drugs than treatments for human desire. We also explain why this summer is shaping up to be a pivotal moment for the treatment of Alzheimer’s and discuss our befuddlement with the latest social media platform.

Listen: The return of bird flu and the effects of pandemic fatigue

STAT

FEBRUARY 9, 2023

Helen Branswell, STAT’s senior writer covering infectious disease, joins us to explain the sudden resurgence of a bird flu virus called H5N1 and why experts are watching the situation closely. We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Read the rest…

BridgeBio’s big week, Lilly’s Alzheimer’s data, & succession at Stanford

STAT

JULY 20, 2023

Neil Kumar, CEO of BridgeBio, joins us to talk about how his small company came to develop what could be a big drug — and why classical Greek literature remains relevant. We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast.

Listen: Fake medical devices, real cancer drugs, & curious Ozempic effects

STAT

JUNE 1, 2023

Why are fake medical devices more lucrative than real ones? Our colleague Lizzy Lawrence joins us to explain the shocking story of a medical device company that sold fake implants and the warped system that made the scam lucrative. Is Ozempic a neurological treatment? And what’s at the cutting edge of oncology?

STAT+: Pharmalittle: We’re reading about Wegovy and Ozempic sales, rising pharma layoffs, and more

STAT

MAY 2, 2024

” To celebrate the notion, we are brewing still more cups of stimulation and inviting you to join us. Sadly, gray skies are hovering over the Pharmalot campus again, but our spirits remain sunny, nonetheless. Our choice today is pistachio creme. Remember, a prescription is not required.

Insurance

Newsletter – March 2024

Fuld

MARCH 14, 2024

Read more Why is Shell shifting its hydrogen strategy? In his latest blog, our Chief Knowledge Officer, Mike Ratcliffe explores why Shell is shifting its hydrogen strategy to focus on hard-to-decarbonize markets. Join us as we welcome Jan to the team! Read more Welcome to the team, Jan Ellsberger!

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

STAT

JUNE 8, 2023

STAT Washington correspondent Rachel Cohrs joins us to explain Merck’s lawsuit against the federal government and why the company believes drug pricing negotiation is “tantamount to extortion.” We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast.

FDA

Listen: How the biotech revolution could come apart at the seams

STAT

NOVEMBER 3, 2022

Why don’t we run better clinical trials? Our colleague Matthew Herper joins us to discuss his thoughtful, personal story on how the biotech revolution that brought us genome editing, Covid-19 vaccines, and lifesaving medicines could run aground if humanity can’t get out of its own way. And how is CRISPR like a Ferrari?

Vaccines

Listen: The FTC v. Amgen, Sarepta’s future, & Galapagos’ turnaround

STAT

MAY 18, 2023

Jared Holz, biotech strategist at Mizuho Securities, joins us to explain why federal regulators are suing to block Amgen’s $28 billion merger with Horizon Therapeutics and what it means for the drug industry. And how do you say “setting cash on fire” in Dutch?

Vaccines

Listen: Explaining the E.U.’s pharma overhaul, Lilly’s booming business, & a long-awaited drug approval

STAT

APRIL 27, 2023

Andrew Joseph, STAT’s Europe correspondent, joins us to explain the EU’s sweeping proposal to overhaul how new drugs are regulated on the continent — and why the pharmaceutical industry is fighting it. We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast.

Listen: Illumina’s boardroom intrigue, the next big Alzheimer’s readout, & J&J’s creative lawyers

STAT

APRIL 6, 2023

Our colleague Matthew Herper joins us for a deep dive into Illumina, explaining how the biggest company in genome sequencing lost the faith of shareholders and painted itself into a corner.

STAT+: Pharmalittle: We’re reading about BIO’s China challenge, Zepbound shortages, and more

STAT

APRIL 18, 2024

” To celebrate the notion, we are brewing still more cups of stimulation and inviting you to join us. Sadly, gray skies are hovering over the Pharmalot campus again, but our spirits remain sunny, nonetheless. Our choice today is pistachio creme. Remember, a prescription is not required.

Listen: How the legal battle over abortion could thwart research, plus: the FDA ‘bully pulpit’ and Moderna’s future

STAT

APRIL 13, 2023

Jeremy Levin, CEO of Ovid Therapeutics, joins us to discuss a judge’s decision to overturn the FDA approval of an abortion pill and why he believes it’s the biggest threat to the biopharma industry in 50 years. We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast.

FDA

Mural Health - giving power to the patients wanting to take part in clinical trials

Outsourcing Pharma

JULY 11, 2023

He joined OSP while at DIA Global to discuss how his business came about and why it is so important. Jason Dong, co-CEO-founder of Mural Health, wants to make sure patients taking part in trials are not out of pocket.

Listen: Leaky health data, ASH22, & what it takes to get booed by your peers

STAT

DECEMBER 15, 2022

Why do billionaires get booed? Katie Palmer, STAT’s health tech correspondent, joins us to explain how the explosive popularity of telehealth is putting sensitive patient information into the hands of Facebook, TikTok, and other big tech firms. How does Facebook end up with sensitive health data?

STAT+: Pharmalittle: We’re reading about abortion pill arguments, a Merck drug approval, and more

STAT

MARCH 27, 2024

And why not? On that optimistic note, please join us for a needed cup or three of stimulation. Hello, everyone, and welcome to the middle of the week. Congratulations on making it this far, because it is an accomplishment, after all. The next step, of course, is to forge ahead. Just consider the alternatives.

FDA

Listen: George Scangos’ retirement, annual Covid vaccines, an Alzheimer’s drug rejection

STAT

JANUARY 26, 2023

Why did the FDA reject an Alzheimer’s treatment? George Scangos, the CEO of Vir Biotechnology, joins us to discuss his retirement and offer some perspective and lessons from a remarkable, 40-year career in biotech. Who needs an annual Covid jab?

Vaccines

Vaccines FDA

STAT+: Pharmalittle: Pfizer projects lower revenue from Covid-19 products; Medicare eyes policy for paying less for accelerated-approval drugs

STAT

FEBRUARY 1, 2023

The middle of the week is upon us and, since you made it this far, why not forge ahead? So please join us as we celebrate this notion with a cup or three of delicious stimulation. As always, please feel free to join us. After all, there is always light at the end of the proverbial tunnel. You never know what you may accomplish.

STAT+: Pharmalittle: PhRMA trade group is losing its edge; Eisai CEO tries to silence critics of Alzheimer’s drug

STAT

NOVEMBER 29, 2022

And why not? ” So go ahead — tug on the ribbon, and join us for a delicious cup of stimulation. As always, do feel free to join us. Gray skies are hovering over the Pharmalot campus this morning, but our spirits remain sunny. Our choice today is the flavorful chocolate raspberry.

STAT+: Pharmalittle: We’re reading about CVS dropping Humira coverage, pharma layoffs, and more

STAT

JANUARY 4, 2024

” To celebrate the notion, we are brewing still more cups of stimulation and invite you to join us. Sadly, gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Remember, a prescription is not required. So no need to mess with rebates.

FDA

Member Spotlight: Thomas Carganico

ISPE

JUNE 7, 2023

He joined the PQE group in 2017 and currently serves as the Vice President of Strategy, Marketing, Communications & Equity Partner. Having joined ISPE in 2020, Thomas wasted no time in getting involved and making the most of his ISPE experience. Why did you join ISPE? I joined ISPE back in 2020, right before Covid.

Communication

STAT+: Pharmalittle: We’re reading about fake Ozempic, the FTC policing pharma, and more

STAT

JANUARY 25, 2024

” To celebrate the notion, we are brewing still more cups of stimulation and invite you to join us. Sadly, gray skies are hovering over the Pharmalot campus again, but our spirits remain sunny, nonetheless. Our choice today is the oh-so-sweet chocolate raspberry.

Labelling

Labelling Compounding FDA

Employee Spotlight: Rob Moore

InCrowd

MARCH 21, 2023

Why did you join Apollo Intelligence? I first joined Apollo in February 2020. I was coming from a bigger organization. I was looking for a growing company. We have continued to grow over the past couple of years and it has been an exciting journey so far.

Communication

Why Go With A PCD Pharma Franchise Company?

Fossil Remedies

MAY 25, 2022

Why should you prefer the best company? Quality assurance is another big benefit when you join a good PCD Pharma Franchise company. Also, good customers join the business, which is always a preferable thing. One more very important benefit of joining PCD Pharma Company is the competitive price. Quality Assurance.

Packaging

STAT+: Pharmalittle: White House takes aim at pharma patents to lower drug prices; Sanofi CEO defends reducing earnings forecast

STAT

DECEMBER 7, 2023

” To celebrate the notion, we are brewing still more cups of stimulation and invite you to join us. Gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Remember, a prescription is not required. So no need to mess with rebates.

STAT+: Pharmalittle: FDA OKs new kind of drug to treat hot flashes; Alzheimer’s drug could cost Medicare up to $5 billion a year

STAT

MAY 15, 2023

So why not give it a nudge in a better direction with a delicious cup of stimulation? Please feel free to join us. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of online calls, dashing about, and deadlines has predictably returned. But what can you do?

FDA

STAT+: Pharmalittle: Online prescribing prompts scrutiny and concern; FDA is pushed to approve OTC birth control pills

STAT

OCTOBER 25, 2022

” To celebrate the notion, we are brewing still more cups of stimulation and invite you to join us. Gray skies are hovering once again over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Our choice today is called Mardi Gras. We will leave it up to you to decipher this blend.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceutical Companies Labelling FDA

STAT+: Pharmalittle: Ohio attorney general accuses PBMs of price fixing; how cost-effectiveness fight could hobble drug price negotiations

STAT

MARCH 28, 2023

” To celebrate the notion, we are brewing still more cups of stimulation and invite you to join us. Steely gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Our flavor today is the aromatic chocolate raspberry.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceutical Companies

STAT+: Pharmalittle: WHO scientist resigns amid shake-up; FDA considers over-the-counter naloxone

STAT

NOVEMBER 16, 2022

The middle of the week is upon us and, since you made it this far, why not forge ahead? So please join us as we celebrate this notion with a cup or three of delicious stimulation. (We Top of the morning to you. After all, there is always light at the end of the proverbial tunnel. You never know what you may accomplish.

Communication

Communication FDA

STAT+: Pharmalittle: Vertex and U.K. at odds over value of CF meds; French authorities probe Sanofi over alleged market manipulation

STAT

NOVEMBER 7, 2023

” To celebrate the notion, we are brewing still more cups of stimulation and invite you to join us. Gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Remember, a prescription is not required. So no need to mess with rebates.

Communication

Why is the healthcare industry hesitant to join the metaverse?

Stanford Health CEO David Entwistle joins Redesign Health's board. Here's why he's bullish on digital health

Trending Sources

Best of the Best: Delaney Santon, CPHT, on How Pharmacy Techs Help Patients

Opinion: Independent doctors like me are becoming an endangered species

Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard

Listen: VC turmoil, GLP-1 competition, & the war on recovery

Evotec to advance drug discovery in collaboration with the Crohn’s & Colitis Foundation

Why a Microbiology Forum is Worth your Time

Biotech layoffs, slumping stocks, and a 2024 preview

Listen: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise

Watch DSN: Walmart Marketplace helps expand product reach to consumers

Prepare for Winter Respiratory Season Testing Needs

Listen: ESMO highlights, Roivant’s big deal, & biotech VC on the rise

Listen: Racing for gene therapy, a pioneering approval, & startups in the lurch

Listen: Wegovy in the brain, pivotal Alzheimer’s data, & pulling Threads

Listen: The return of bird flu and the effects of pandemic fatigue

BridgeBio’s big week, Lilly’s Alzheimer’s data, & succession at Stanford

Listen: Fake medical devices, real cancer drugs, & curious Ozempic effects

STAT+: Pharmalittle: We’re reading about Wegovy and Ozempic sales, rising pharma layoffs, and more

Newsletter – March 2024

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

Listen: How the biotech revolution could come apart at the seams

Listen: The FTC v. Amgen, Sarepta’s future, & Galapagos’ turnaround

Listen: Explaining the E.U.’s pharma overhaul, Lilly’s booming business, & a long-awaited drug approval

Listen: Illumina’s boardroom intrigue, the next big Alzheimer’s readout, & J&J’s creative lawyers

STAT+: Pharmalittle: We’re reading about BIO’s China challenge, Zepbound shortages, and more

Listen: How the legal battle over abortion could thwart research, plus: the FDA ‘bully pulpit’ and Moderna’s future

Mural Health - giving power to the patients wanting to take part in clinical trials

Listen: Leaky health data, ASH22, & what it takes to get booed by your peers

STAT+: Pharmalittle: We’re reading about abortion pill arguments, a Merck drug approval, and more

Listen: George Scangos’ retirement, annual Covid vaccines, an Alzheimer’s drug rejection

STAT+: Pharmalittle: Pfizer projects lower revenue from Covid-19 products; Medicare eyes policy for paying less for accelerated-approval drugs

STAT+: Pharmalittle: PhRMA trade group is losing its edge; Eisai CEO tries to silence critics of Alzheimer’s drug

STAT+: Pharmalittle: We’re reading about CVS dropping Humira coverage, pharma layoffs, and more

Member Spotlight: Thomas Carganico

STAT+: Pharmalittle: We’re reading about fake Ozempic, the FTC policing pharma, and more

Employee Spotlight: Rob Moore

Why Go With A PCD Pharma Franchise Company?

STAT+: Pharmalittle: White House takes aim at pharma patents to lower drug prices; Sanofi CEO defends reducing earnings forecast

STAT+: Pharmalittle: FDA OKs new kind of drug to treat hot flashes; Alzheimer’s drug could cost Medicare up to $5 billion a year

STAT+: Pharmalittle: Online prescribing prompts scrutiny and concern; FDA is pushed to approve OTC birth control pills

STAT+: Pharmalittle: Ohio attorney general accuses PBMs of price fixing; how cost-effectiveness fight could hobble drug price negotiations

STAT+: Pharmalittle: WHO scientist resigns amid shake-up; FDA considers over-the-counter naloxone

STAT+: Pharmalittle: Vertex and U.K. at odds over value of CF meds; French authorities probe Sanofi over alleged market manipulation

Stay Connected